CG Oncology (NASDAQ:CGON – Get Free Report) and Myriad Genetics (NASDAQ:MYGN – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, profitability, valuation and dividends.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for CG Oncology and Myriad Genetics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CG Oncology | 1 | 1 | 8 | 0 | 2.70 |
| Myriad Genetics | 3 | 4 | 1 | 0 | 1.75 |
CG Oncology presently has a consensus price target of $87.50, suggesting a potential upside of 41.49%. Myriad Genetics has a consensus price target of $4.02, suggesting a potential downside of 3.21%. Given CG Oncology’s stronger consensus rating and higher probable upside, equities analysts clearly believe CG Oncology is more favorable than Myriad Genetics.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| CG Oncology | -3,602.68% | -25.20% | -23.98% |
| Myriad Genetics | -13.96% | -16.09% | -8.10% |
Institutional & Insider Ownership
26.6% of CG Oncology shares are held by institutional investors. Comparatively, 99.0% of Myriad Genetics shares are held by institutional investors. 4.8% of CG Oncology shares are held by insiders. Comparatively, 1.9% of Myriad Genetics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Risk and Volatility
CG Oncology has a beta of 0.28, meaning that its share price is 72% less volatile than the S&P 500. Comparatively, Myriad Genetics has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500.
Valuation and Earnings
This table compares CG Oncology and Myriad Genetics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CG Oncology | $4.04 million | 1,356.81 | -$160.99 million | ($2.69) | -22.99 |
| Myriad Genetics | $824.50 million | 0.48 | -$365.90 million | ($1.19) | -3.49 |
CG Oncology has higher earnings, but lower revenue than Myriad Genetics. CG Oncology is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.
Summary
Myriad Genetics beats CG Oncology on 8 of the 14 factors compared between the two stocks.
About CG Oncology
CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.
About Myriad Genetics
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.
Receive News & Ratings for CG Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CG Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
